Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Belviq, Belviq XR
Lorcaserin is a weight-loss medication that acts as a selective serotonin 2C receptor agonist in the hypothalamus, a region of the brain that regulates appetite. It was approved by the FDA in 2012 but later withdrawn in 2020 due to an increased risk of certain cancers. It belongs to the class of serotonergic anorectics and was intended for use in adults with a body mass index (BMI) of 30 or greater (obese) or 27 or greater (overweight) with at least one weight-related comorbidity, such as high blood pressure, type 2 diabetes, or high cholesterol.
Lorcaserin was used for chronic weight management in adults with obesity or overweight with weight-related comorbidities.
Outcome:
Serotonin syndrome
Mechanism:
Increased serotonin levels
Outcome:
Increased risk of serotonin syndrome
Mechanism:
Altered serotonin metabolism
Outcome:
Reduced absorption of lorcaserin
Mechanism:
Changes in gastric pH
No new formulations of lorcaserin are anticipated due to safety concerns.
Due to the drug's withdrawal, the likelihood of its reintroduction is extremely low (<1%).
Serotonin 2C Receptor Agonist, Anorectic
Arylpiperazine